SRX Health Solutions Inc. Announces Private Placement of Series B Convertible Preferred Stock and Warrants

Key Developments from Recent 8-K Filing

SRX Health Solutions Inc. (NYSE American: [TICKER]) has entered into a significant financing transaction through a private placement of its Series B Convertible Preferred Stock and related warrants, as detailed in its recent Form 8-K filing. This development could have material implications for current and prospective shareholders.

Key Points and Investor-Relevant Details

• Private Placement Agreement: On March 16, 2026, SRX Health Solutions executed a Securities Purchase Agreement with a group of investors for the issuance of Series B Convertible Preferred Stock and accompanying warrants.
• Terms of the Series B Preferred Stock:
  • Dividends: Holders of Series B Preferred Stock are entitled to dividends on an “as-if converted” basis, matching any dividends paid to common shareholders, if and when paid.
  • Conversion Rights: Each share of Series B Preferred Stock is convertible into common stock at a fixed conversion price, subject to adjustments. Investors also have an “Alternate Optional Conversion” right to convert at the lower of the fixed price or 95% of the lowest volume weighted average price (VWAP) over the five trading days prior to conversion, after shareholder approval.
  • Voluntary Adjustment: With investor consent, the board may lower the conversion price at any time, subject to NYSE American regulations.
  • Stockholder Approval: The company is required to seek shareholder approval for the full conversion of Series B shares and the exercise of warrants, as per NYSE American listing rules.
  • Protection Against Dilution: The company must reserve at least 200% of the shares needed to cover all potential conversions of Series B Preferred Stock.
  • Redemption and Triggering Events: Certain events (including bankruptcy, failure to file/maintain registration statements, and breaches of covenant) trigger mandatory redemption of the Preferred Stock at a premium and could be considered events of default.
• Warrants: The agreement also grants warrants to purchase additional common shares under specified terms, further increasing potential dilution.
• Registration Rights: SRX Health Solutions must file a registration statement with the SEC to register for resale the common stock issuable upon conversion of the Series B Preferred Stock and upon exercise of the warrants.
• Unregistered Offering: The securities are offered in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
• Restrictions on Corporate Actions:
  • Company is restricted from incurring new indebtedness or liens, issuing new preferred shares, repurchasing shares, or making certain restricted payments without consent of Series B holders.
  • Change of control, material adverse events, or significant breaches may trigger investor protections or redemption rights.
• Voting and Governance: Series B holders have protective voting rights. The company cannot amend organizational documents or take certain actions that adversely affect the Series B Preferred Stock without the consent of the holders.
• Transfer Rights: Series B Preferred Stock can be transferred by holders, subject to the Securities Purchase Agreement.
• Ongoing Compliance: The company must maintain PCAOB-registered auditors, stay in good standing, and provide timely disclosures and notices to Series B holders.

Potentially Price-Sensitive or Material Factors for Shareholders

• Significant Dilution Risk: The conversion rights and warrants could result in substantial dilution to existing common shareholders, especially if the conversion price is adjusted downward or if stock price declines.
• Stockholder Approval Requirement: The transaction is contingent on shareholder approval. Failure to obtain approval could impact the company’s ability to raise capital, while approval and subsequent conversions could impact share value and control dynamics.
• Protective Covenants: The Preferred Stock imposes restrictions on new debt, dividends, asset sales, and business changes, which could impact the company’s flexibility and strategic options.
• Potential for Redemption at a Premium: Triggering events, including bankruptcy, non-compliance, or adverse changes, may require the company to redeem Preferred Shares at a premium, impacting liquidity and financial stability.
• Mandatory Registration: The company is obligated to file and maintain effectiveness of a registration statement for resale of the underlying common shares, with penalties for non-compliance.
• Investor Oversight: Series B holders have the right to commission independent investigations in the event of suspected breaches, granting them significant oversight rights.

Exhibits and Additional Documents

• Form of Certificate of Designations of Rights and Preferences and Limitations of the Series B Convertible Preferred Stock
• Form of Warrant
• Securities Purchase Agreement dated March 16, 2026
• Registration Rights Agreement

Conclusion

This private placement is a significant capital raise for SRX Health Solutions Inc. However, the structure of the Series B Convertible Preferred Stock and the associated warrants introduce substantial dilution risk, new governance considerations, and a number of protective provisions for new investors that could materially impact current shareholders. The requirement for shareholder approval and the various triggers for mandatory redemption or adjustments in conversion terms are especially important for investors to monitor, as they may have direct implications for the company’s share price and capital structure.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should consult their financial advisor and review the full SEC filings and exhibits for complete details and before making any investment decisions.

View SRx Health Solutions, Inc. Historical chart here